Skip to content

news

Press release | 2022-06-14

NEOGAP Therapeutic’s patented method opens for new individualised treatment of MS in Swedish in English

A recent study shows that a part of NEOGAP Therapeutics’ patented method for developing individualised immunotherapy for cancer treatment can also be used to identify which immune cells are involved in autoimmune diseases. In the study, four new target molecules for MS have been discovered.

Press release | 2022-05-05

New publication strengthens NEOGAP Therapeutics’ patented technology and shows that it can also be used for proliferation of T cells from blood in Swedish in English

NEOGAP Therapeutics, which develops an individualised immunotherapy for treatment of cancer, presents in a publication together with researchers at Karolinska Institutet, preclinical data that further show that the company’s in-house developed technology EpiTCer® has the ability to effectively produce tumour-specific T cells.

Press release | 2022-03-24

The immunotherapy company NEOGAP Therapeutics AB contracts CRO for their first clinical trial for cancer (in Swedish)

NEOGAP Therapeutics AB, which develops an individualised immunotherapy for treatment of cancer, announces that Swedish CTC (Clinical Trial Consultants AB) has been chosen as the CRO (Contract Research Organisation) for the planned clinical phase I / IIa trial in colorectal cancer, which is expected to start in 2022.

Press release | 2022-02-28

NEOGAP Therapeutics AB, a Swedish immunotherapy company, raises 58 MSEK for a clinical trial for cancer (in Swedish)

Together with Sciety AB, a Swedish investor network, NEOGAP Therapeutics AB has completed a new issue of 58 million SEK. The capital raised will be used for a clinical first-in-human trial (phase I / IIa) in colorectal cancer, which is expected to start in 2022.